drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00342 | DB08864 | 1,181 | 786 | [
"DDInter1770",
"DDInter1595"
] | Terfenadine | Rilpivirine | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior. | Moderate | 1 | [
[
[
1181,
24,
786
]
],
[
[
1181,
24,
655
],
[
655,
1,
786
]
],
[
[
1181,
23,
112
],
[
112,
23,
786
]
],
[
[
1181,
24,
1017
],
[
1017,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rilpivirine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Terfenadine may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Terfenadine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Terfenadine may lead to a major life threatening interaction when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Terfenadine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Rilpivirine |
DB06636 | DB14568 | 1,623 | 982 | [
"DDInter980",
"DDInter1000"
] | Isavuconazonium | Ivosidenib | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Major | 2 | [
[
[
1623,
25,
982
]
],
[
[
1623,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1623,
24,
976
],
[
976,
24,
982
]
],
[
[
1623,
63,
543
],
[
543,
... | [
[
[
"Isavuconazonium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"... | Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Isavuconazonium may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Isavuconazonium may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Ivosidenib
Isavuconazonium may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Ivosidenib |
DB00060 | DB00851 | 912 | 611 | [
"DDInter947",
"DDInter463"
] | Interferon beta-1a | Dacarbazine | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Moderate | 1 | [
[
[
912,
24,
611
]
],
[
[
912,
24,
1176
],
[
1176,
23,
611
]
],
[
[
912,
24,
850
],
[
850,
63,
611
]
],
[
[
912,
63,
305
],
[
305,
2... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxac... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Interferon beta-1a may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Dacarbazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Dacarbazine
Interferon beta-1a may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Dacarbazine
Interferon beta-1a may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Dacarbazine |
DB05773 | DB08889 | 1,047 | 350 | [
"DDInter1848",
"DDInter299"
] | Trastuzumab emtansine | Carfilzomib | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trast | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy. | Moderate | 1 | [
[
[
1047,
24,
350
]
],
[
[
1047,
24,
1060
],
[
1060,
63,
350
]
],
[
[
1047,
63,
482
],
[
482,
24,
350
]
],
[
[
1047,
24,
310
],
[
310,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfo... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Carfilzomib
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Mipomersen and Mipomersen may lead to a major life threatening interaction when taken with Carfilzomib
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Carfilzomib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Carfilzomib |
DB01069 | DB12161 | 401 | 730 | [
"DDInter1533",
"DDInter512"
] | Promethazine | Deutetrabenazine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound . This allows less frequent dosing and a lower daily dose with improvement in tolerability . Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine . Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and neuropsychiatric disturbances that interfere with daily functioning and significantly reduce the quality of life. The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions . Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission . Deutetrabenazine depletes the levels of presynaptic dopamine by blocking VMAT2, which is responsible for the uptake of dopamine into synaptic vesicles in monoaminergic neurons and exocytotic release . As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease . In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo . It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. | Major | 2 | [
[
[
401,
25,
730
]
],
[
[
401,
62,
112
],
[
112,
23,
730
]
],
[
[
401,
63,
322
],
[
322,
24,
730
]
],
[
[
401,
24,
971
],
[
971,
24,... | [
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib and Dacomitinib may lead to a major life threatening interaction when taken with Deutetrabenazine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may lead to a major life threatening interaction when taken with Deutetrabenazine
Promethazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Deutetrabenazine
Promethazine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Deutetrabenazine |
DB00852 | DB08918 | 1,445 | 41 | [
"DDInter1545",
"DDInter1059"
] | Pseudoephedrine | Levomilnacipran | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use. | Moderate | 1 | [
[
[
1445,
24,
41
]
],
[
[
1445,
24,
901
],
[
901,
40,
41
]
],
[
[
1445,
6,
6112
],
[
6112,
45,
41
]
],
[
[
1445,
21,
28975
],
[
28975,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Pseudoephedrine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Levomilnacipran (Compound)
Pseudoephedrine (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Levomilnacipran (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Pseudoephedrine (Compound) resembles Ephedrine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Pseudoephedrine (Compound) resembles Phenylpropanolamine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may lead to a major life threatening interaction when taken with Levomilnacipran
Pseudoephedrine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Levomilnacipran |
DB00031 | DB00790 | 20 | 664 | [
"DDInter1764",
"DDInter1431"
] | Tenecteplase | Perindopril | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain. | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. | Moderate | 1 | [
[
[
20,
24,
664
]
],
[
[
20,
24,
1638
],
[
1638,
1,
664
]
],
[
[
20,
24,
954
],
[
954,
40,
664
]
],
[
[
20,
24,
885
],
[
885,
63,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Perindopril (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Perindopril
Tenecteplase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Perindopril
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Perindopril
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Ramipril (Compound) and Ramipril (Compound) resembles Perindopril (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Trandolapril (Compound) and Trandolapril (Compound) resembles Perindopril (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Tenecteplase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound) |
DB00227 | DB06186 | 1,463 | 1,439 | [
"DDInter1098",
"DDInter969"
] | Lovastatin | Ipilimumab | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011. | Moderate | 1 | [
[
[
1463,
24,
1439
]
],
[
[
1463,
63,
912
],
[
912,
24,
1439
]
],
[
[
1463,
24,
482
],
[
482,
24,
1439
]
],
[
[
1463,
24,
310
],
[
310,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Lovastatin (Compound) resembles Pravastatin (Compound) and Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Lovastatin (Compound) resembles Simvastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Lovastatin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Lovastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ipilimumab
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Ipilimumab
Lovastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ipilimumab |
DB00491 | DB00701 | 127 | 1,091 | [
"DDInter1217",
"DDInter90"
] | Miglitol | Amprenavir | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. | Amprenavir is a protease inhibitor used to treat HIV infection. | Moderate | 1 | [
[
[
127,
24,
1091
]
],
[
[
127,
24,
34
],
[
34,
1,
1091
]
],
[
[
127,
21,
28810
],
[
28810,
60,
1091
]
],
[
[
127,
24,
222
],
[
222,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir (Compound) resembles Amprenavir (Compound)
Miglitol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Amprenavir (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Amprenavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Amprenavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may lead to a major life threatening interaction when taken with Amprenavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir (Compound) resembles Darunavir (Compound) and Darunavir (Compound) resembles Amprenavir (Compound) |
DB09115 | DB09570 | 505 | 1,480 | [
"DDInter559",
"DDInter1002"
] | Diiodohydroxyquinoline | Ixazomib | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. | Moderate | 1 | [
[
[
505,
24,
1480
]
],
[
[
505,
63,
268
],
[
268,
24,
1480
]
],
[
[
505,
24,
148
],
[
148,
63,
1480
]
],
[
[
505,
63,
375
],
[
375,
... | [
[
[
"Diiodohydroxyquinoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Diiodohydroxyquinoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegin... | Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Ixazomib
Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib |
DB00035 | DB00477 | 1,314 | 216 | [
"DDInter507",
"DDInter363"
] | Desmopressin | Chlorpromazine | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems. Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH. It has been employed clinically since 1972 | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Moderate | 1 | [
[
[
1314,
24,
216
]
],
[
[
1314,
24,
1237
],
[
1237,
40,
216
]
],
[
[
1314,
24,
1164
],
[
1164,
1,
216
]
],
[
[
1314,
21,
28751
],
[
28751... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Chlorpromazine (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Chlorpromazine (Compound)
Desmopressin (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Chlorpromazine (Compound)
Desmopressin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine
Desmopressin (Compound) resembles Pasireotide (Compound) and Pasireotide may lead to a major life threatening interaction when taken with Chlorpromazine
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Chlorpromazine
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Prochlorperazine (Compound) and Prochlorperazine (Compound) resembles Chlorpromazine (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Ethopropazine (Compound) and Ethopropazine (Compound) resembles Chlorpromazine (Compound) |
DB01226 | DB01233 | 1,319 | 1,311 | [
"DDInter1235",
"DDInter1197"
] | Mivacurium | Metoclopramide | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980. | Moderate | 1 | [
[
[
1319,
24,
1311
]
],
[
[
1319,
21,
28680
],
[
28680,
60,
1311
]
],
[
[
1319,
63,
1620
],
[
1620,
23,
1311
]
],
[
[
1319,
21,
28680
],
[
... | [
[
[
"Mivacurium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Mivacurium",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by ... | Mivacurium (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Metoclopramide (Compound)
Mivacurium may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Mivacurium (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Procaine (Compound) and Procaine (Compound) resembles Metoclopramide (Compound)
Mivacurium (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Acetaminophen (Compound) and Acetaminophen may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Mivacurium (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Sunitinib (Compound) and Sunitinib (Compound) resembles Metoclopramide (Compound)
Mivacurium (Compound) resembles Atracurium (Compound) and Atracurium (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Metoclopramide (Compound)
Mivacurium may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Mivacurium (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Vecuronium (Compound) and Vecuronium may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Mivacurium (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Procainamide (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide |
DB00163 | DB08871 | 1,461 | 36 | [
"DDInter1943",
"DDInter666"
] | Vitamin E | Eribulin | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label]. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors . | Moderate | 1 | [
[
[
1461,
24,
36
]
],
[
[
1461,
24,
1488
],
[
1488,
24,
36
]
],
[
[
1461,
23,
1683
],
[
1683,
24,
36
]
],
[
[
1461,
24,
1480
],
[
1480,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Eribulin
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Eribulin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Eribulin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Eribulin |
DB05294 | DB06603 | 1,069 | 39 | [
"DDInter1917",
"DDInter1387"
] | Vandetanib | Panobinostat | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Major | 2 | [
[
[
1069,
25,
39
]
],
[
[
1069,
62,
1247
],
[
1247,
23,
39
]
],
[
[
1069,
63,
479
],
[
479,
23,
39
]
],
[
[
1069,
63,
867
],
[
867,
... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Vandetanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulf... | Vandetanib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Vandetanib may lead to a major life threatening interaction when taken with Ivabradine and Ivabradine may lead to a major life threatening interaction when taken with Panobinostat
Vandetanib may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole may lead to a major life threatening interaction when taken with Panobinostat
Vandetanib (Compound) resembles Bosutinib (Compound) and Vandetanib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Panobinostat
Vandetanib may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Panobinostat |
DB08901 | DB09118 | 1,468 | 1,580 | [
"DDInter1492",
"DDInter1711"
] | Ponatinib | Stiripentol | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit. | Moderate | 1 | [
[
[
1468,
24,
1580
]
],
[
[
1468,
64,
1409
],
[
1409,
24,
1580
]
],
[
[
1468,
25,
283
],
[
283,
63,
1580
]
],
[
[
1468,
63,
168
],
[
168,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
... | Ponatinib may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ponatinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ponatinib (Compound) resembles Imatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ponatinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ponatinib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Stiripentol |
DB00734 | DB14723 | 1,664 | 159 | [
"DDInter1605",
"DDInter1026"
] | Risperidone | Larotrectinib | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
1664,
24,
159
]
],
[
[
1664,
24,
222
],
[
222,
23,
159
]
],
[
[
1664,
24,
741
],
[
741,
24,
159
]
],
[
[
1664,
63,
1181
],
[
1181,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Risperidone may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Risperidone may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Risperidone (Compound) resembles Iloperidone (Compound) and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Risperidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib
Risperidone may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Larotrectinib |
DB00372 | DB00477 | 999 | 216 | [
"DDInter1793",
"DDInter363"
] | Thiethylperazine | Chlorpromazine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Moderate | 1 | [
[
[
999,
24,
216
]
],
[
[
999,
24,
1178
],
[
1178,
1,
216
]
],
[
[
999,
63,
902
],
[
902,
40,
216
]
],
[
[
999,
24,
1216
],
[
1216,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluopera... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Chlorpromazine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Chlorpromazine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine
Thiethylperazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Chlorpromazine (Compound)
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Chlorpromazine
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Chlorpromazine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine |
DB00910 | DB06448 | 1,041 | 171 | [
"DDInter1394",
"DDInter1087"
] | Paricalcitol | Lonafarnib | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.[A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] | Moderate | 1 | [
[
[
1041,
24,
171
]
],
[
[
1041,
24,
98
],
[
98,
63,
171
]
],
[
[
1041,
24,
86
],
[
86,
24,
171
]
],
[
[
1041,
24,
129
],
[
129,
64,... | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
... | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lonafarnib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Lonafarnib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Paricalcitol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a minor interaction that can limit clinical effects when taken with Loratadine and Loratadine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib |
DB01159 | DB04868 | 419 | 478 | [
"DDInter854",
"DDInter1293"
] | Halothane | Nilotinib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Major | 2 | [
[
[
419,
25,
478
]
],
[
[
419,
6,
6017
],
[
6017,
45,
478
]
],
[
[
419,
62,
112
],
[
112,
23,
478
]
],
[
[
419,
24,
1040
],
[
1040,
... | [
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Halothane",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"... | Halothane (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Halothane may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Nilotinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Nilotinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may lead to a major life threatening interaction when taken with Nilotinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Nilotinib |
DB01144 | DB08907 | 1,326 | 1,344 | [
"DDInter540",
"DDInter280"
] | Diclofenamide | Canagliflozin | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
1326,
24,
1344
]
],
[
[
1326,
24,
549
],
[
549,
1,
1344
]
],
[
[
1326,
21,
28680
],
[
28680,
60,
1344
]
],
[
[
1326,
63,
1486
],
[
148... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Diclofenamide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Canagliflozin (Compound)
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Diclofenamide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) binds SLC5A1 (Gene) and SLC5A1 (Gene) is bound by Canagliflozin (Compound)
Diclofenamide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin (Compound) resembles Canagliflozin (Compound) |
DB01114 | DB14881 | 272 | 180 | [
"DDInter362",
"DDInter1329"
] | Chlorpheniramine | Oliceridine | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™. | Moderate | 1 | [
[
[
272,
24,
180
]
],
[
[
272,
63,
401
],
[
401,
24,
180
]
],
[
[
272,
24,
649
],
[
649,
24,
180
]
],
[
[
272,
74,
100
],
[
100,
24,... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Chlorpheniramine (Compound) resembles Brompheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Chlorpheniramine (Compound) resembles Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Oliceridine
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Oliceridine
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine |
DB00848 | DB15091 | 281 | 676 | [
"DDInter1044",
"DDInter1901"
] | Levamisole | Upadacitinib | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis. Because of its immunomodulatory effects, this drug has been studied in the treatment of various immune-mediated diseases, with some studies showing positive results. This drug has also been used in combination with other drugs for the treatment of various cancers. [A178117, A178123] Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranul | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
281,
25,
676
]
],
[
[
281,
24,
1430
],
[
1430,
24,
676
]
],
[
[
281,
63,
597
],
[
597,
24,
676
]
],
[
[
281,
63,
1184
],
[
1184,
... | [
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipule... | Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may lead to a major life threatening interaction when taken with Upadacitinib
Levamisole may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Upadacitinib
Levamisole may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Upadacitinib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound) and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib |
DB00861 | DB01240 | 914 | 885 | [
"DDInter551",
"DDInter657"
] | Diflunisal | Epoprostenol | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
914,
24,
885
]
],
[
[
914,
63,
1061
],
[
1061,
1,
885
]
],
[
[
914,
21,
28936
],
[
28936,
60,
885
]
],
[
[
914,
63,
1512
],
[
1512,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Diflunisal (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Epoprostenol (Compound)
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin and Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Diflunisal may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Diflunisal may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Diflunisal (Compound) resembles Flurbiprofen (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Diflunisal may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Epoprostenol |
DB01082 | DB14115 | 1,448 | 1,312 | [
"DDInter1713",
"DDInter868"
] | Streptomycin | Human botulinum neurotoxin A/B immune globulin | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis. | Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle tone (e.g. constipation, ptosis, feeding difficulties) which may progress to more serious symptoms such as respiratory arrest and flaccid paralysis.[L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003 and has since been used to treat more than 2100 cases of infant botulism. It is produced and distributed by the Calfornia Department of Public Health's Infant Botulism Treatment and Prevention Program and comprises IgG antibodies derived from pooled adult plasma from persons immunized with recombinant botulinum vaccine who have high titers of neutralizing antibodies against botulinum toxin. | Major | 2 | [
[
[
1448,
25,
1312
]
],
[
[
1448,
24,
123
],
[
123,
24,
1312
]
],
[
[
1448,
63,
1132
],
[
1132,
25,
1312
]
],
[
[
1448,
35,
416
],
[
416,
... | [
[
[
"Streptomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human botulinum neurotoxin A/B immune globulin"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ex... | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Human botulinum neurotoxin A/B immune globulin
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Streptomycin (Compound) resembles Kanamycin (Compound) and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Streptomycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Human botulinum neurotoxin A/B immune globulin
Streptomycin (Compound) resembles Kanamycin (Compound) and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Human botulinum neurotoxin A/B immune globulin
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Human botulinum neurotoxin A/B immune globulin |
DB00787 | DB09134 | 387 | 1,552 | [
"DDInter25",
"DDInter966"
] | Acyclovir | Ioversol | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old. Acyclovir was granted FDA approval on 29 March 1982. | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol, enhances the contrast between vessels in the path of the flow of the contrast medium and normal tissue, allowing the visualization of internal structures. Ioversol is a highly hydrophilic agent considered to be generally safe; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol, which is only indicated for intra-arterial and intravenous use. Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left ventriculography.[L41780,L41790] | Major | 2 | [
[
[
387,
25,
1552
]
],
[
[
387,
24,
242
],
[
242,
63,
1552
]
],
[
[
387,
40,
1295
],
[
1295,
25,
1552
]
],
[
[
387,
24,
1381
],
[
1381,
... | [
[
[
"Acyclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
... | Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Acyclovir (Compound) resembles Valaciclovir (Compound) and Valaciclovir may lead to a major life threatening interaction when taken with Ioversol
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin and Plazomicin may lead to a major life threatening interaction when taken with Ioversol
Acyclovir may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Ioversol
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Ioversol
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Ioversol
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Acyclovir (Compound) resembles Valaciclovir (Compound) and Valaciclovir may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin and Plazomicin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Ioversol |
DB00678 | DB01075 | 240 | 1,376 | [
"DDInter1095",
"DDInter569"
] | Losartan | Diphenhydramine | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide]. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties. | Moderate | 1 | [
[
[
240,
24,
1376
]
],
[
[
240,
24,
401
],
[
401,
24,
1376
]
],
[
[
240,
6,
10215
],
[
10215,
45,
1376
]
],
[
[
240,
21,
28921
],
[
28921,... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[... | Losartan may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Losartan (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Diphenhydramine (Compound)
Losartan (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Diphenhydramine (Compound)
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Losartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Losartan (Compound) resembles Olmesartan (Compound) and Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Losartan may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Diphenhydramine
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Diphenhydramine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine |
DB00731 | DB00741 | 1,144 | 167 | [
"DDInter1269",
"DDInter885"
] | Nateglinide | Hydrocortisone | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Moderate | 1 | [
[
[
1144,
24,
167
]
],
[
[
1144,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1144,
63,
303
],
[
303,
40,
167
]
],
[
[
1144,
63,
870
],
[
870,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) resembles Hydrocortisone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydrocortisone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Hydrocortisone (Compound)
Nateglinide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Hydrocortisone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone |
DB09074 | DB09098 | 1,362 | 98 | [
"DDInter1327",
"DDInter1700"
] | Olaparib | Somatrem | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
1362,
24,
98
]
],
[
[
1362,
63,
608
],
[
608,
23,
98
]
],
[
[
1362,
63,
336
],
[
336,
24,
98
]
],
[
[
1362,
24,
159
],
[
159,
63... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Li... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Olaparib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Olaparib may lead to a major life threatening interaction when taken with Stiripentol and Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somatrem
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem |
DB00619 | DB09143 | 1,419 | 313 | [
"DDInter909",
"DDInter1701"
] | Imatinib | Sonidegib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
1419,
25,
313
]
],
[
[
1419,
24,
101
],
[
101,
23,
313
]
],
[
[
1419,
63,
1215
],
[
1215,
23,
313
]
],
[
[
1419,
35,
478
],
[
478,
... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansopr... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Imatinib (Compound) resembles Nilotinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Imatinib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Imatinib may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib |
DB00402 | DB01081 | 1,407 | 1,688 | [
"DDInter685",
"DDInter571"
] | Eszopiclone | Diphenoxylate | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia. One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia. This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004. | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II. | Moderate | 1 | [
[
[
1407,
24,
1688
]
],
[
[
1407,
24,
1118
],
[
1118,
1,
1688
]
],
[
[
1407,
24,
128
],
[
128,
24,
1688
]
],
[
[
1407,
63,
1594
],
[
1594,... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
],
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin and Difenoxin (Compound) resembles Diphenoxylate (Compound)
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin and Difenoxin (Compound) resembles Methadone (Compound) and Methadone (Compound) resembles Diphenoxylate (Compound)
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Diphenoxylate (Compound)
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Methadone (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Diphenoxylate (Compound)
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Methadone (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Diphenoxylate (Compound)
Eszopiclone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Methadone (Compound) and Methadone (Compound) resembles Diphenoxylate (Compound) |
DB00209 | DB01324 | 352 | 178 | [
"DDInter1886",
"DDInter1490"
] | Trospium | Polythiazide | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Minor | 0 | [
[
[
352,
23,
178
]
],
[
[
352,
23,
674
],
[
674,
40,
178
]
],
[
[
352,
21,
28714
],
[
28714,
60,
178
]
],
[
[
352,
24,
85
],
[
85,
2... | [
[
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
]
],
[
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
],
[
... | Trospium may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Trospium (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Polythiazide (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Trospium (Compound) resembles Clidinium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Trospium may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide (Compound) resembles Polythiazide (Compound)
Trospium may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide (Compound) resembles Polythiazide (Compound) |
DB00039 | DB00112 | 1,253 | 374 | [
"DDInter1380",
"DDInter201"
] | Palifermin | Bevacizumab | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.[A192834,A192888,A192837,A192891,A192894] In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market.[A193272,A193275] It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A.[A192888,A192939] Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer. Bevacizumab was approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021.[L45793,L43130] There are several biosimilars of bevacizumab, such as bevacizumab-awwb, bevacizumab-maly, bevacizumab-adcd, and bevacizumab-tnjn. Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies including acute respiratory syndrome (ARDS) and acute lung injury (ALI). As such, bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19. | Moderate | 1 | [
[
[
1253,
24,
374
]
],
[
[
1253,
24,
869
],
[
869,
63,
374
]
],
[
[
1253,
24,
770
],
[
770,
64,
374
]
],
[
[
1253,
24,
869
],
[
869,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bevacizumab"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Bevacizumab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Bevacizumab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Bevacizumab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ibandronate and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Bevacizumab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Bevacizumab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Bevacizumab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Bevacizumab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Bevacizumab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Bevacizumab |
DB00816 | DB01267 | 1,674 | 519 | [
"DDInter1346",
"DDInter1381"
] | Orciprenaline | Paliperidone | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Moderate | 1 | [
[
[
1674,
24,
519
]
],
[
[
1674,
63,
1664
],
[
1664,
1,
519
]
],
[
[
1674,
25,
924
],
[
924,
1,
519
]
],
[
[
1674,
21,
28658
],
[
28658,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Orciprenaline may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Orciprenaline (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Paliperidone (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Orciprenaline (Compound) resembles Isoprenaline (Compound) and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone |
DB08901 | DB13007 | 1,468 | 1,060 | [
"DDInter1492",
"DDInter642"
] | Ponatinib | Enfortumab vedotin | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022. | Moderate | 1 | [
[
[
1468,
24,
1060
]
],
[
[
1468,
24,
1604
],
[
1604,
23,
1060
]
],
[
[
1468,
63,
129
],
[
129,
23,
1060
]
],
[
[
1468,
63,
1593
],
[
1593... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ponatinib (Compound) resembles Imatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ponatinib may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ponatinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ponatinib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Enfortumab vedotin
Ponatinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Enfortumab vedotin |
DB06016 | DB12332 | 1,508 | 1,619 | [
"DDInter300",
"DDInter1626"
] | Cariprazine | Rucaparib | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198] | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1508,
24,
1619
]
],
[
[
1508,
63,
222
],
[
222,
23,
1619
]
],
[
[
1508,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
1508,
63,
1419
],
[
1419... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Cariprazine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Cariprazine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Rucaparib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Rucaparib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Rucaparib |
DB08895 | DB13007 | 976 | 1,060 | [
"DDInter1825",
"DDInter642"
] | Tofacitinib | Enfortumab vedotin | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022. | Major | 2 | [
[
[
976,
25,
1060
]
],
[
[
976,
25,
1604
],
[
1604,
23,
1060
]
],
[
[
976,
63,
1593
],
[
1593,
24,
1060
]
],
[
[
976,
25,
270
],
[
270,
... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
... | Tofacitinib may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Tofacitinib may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Tofacitinib may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Enfortumab vedotin
Tofacitinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Enfortumab vedotin
Tofacitinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Enfortumab vedotin
Tofacitinib may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin |
DB00277 | DB00759 | 1,031 | 1,620 | [
"DDInter1791",
"DDInter1783"
] | Theophylline | Tetracycline | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells. The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used. | Moderate | 1 | [
[
[
1031,
24,
1620
]
],
[
[
1031,
24,
1572
],
[
1572,
40,
1620
]
],
[
[
1031,
63,
964
],
[
964,
40,
1620
]
],
[
[
1031,
6,
8374
],
[
8374,... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
]... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Tetracycline (Compound)
Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tetracycline (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Tetracycline
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a minor interaction that can limit clinical effects when taken with Tetracycline
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline
Theophylline may cause a minor interaction that can limit clinical effects when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Succinylcholine and Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline
Theophylline may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline |
DB00539 | DB15982 | 11 | 1,339 | [
"DDInter1837",
"DDInter193"
] | Toremifene | Berotralstat | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to prevent, but not treat, these attacks. Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. Berotralstat was approved by the European Commission on April 30, 2021 and by Health Canada on June 06, 2022. | Moderate | 1 | [
[
[
11,
24,
1339
]
],
[
[
11,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
11,
24,
283
],
[
283,
23,
1339
]
],
[
[
11,
25,
1213
],
[
1213,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Toremifene may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Toremifene (Compound) resembles Tamoxifen (Compound) and Toremifene may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Toremifene may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Toremifene (Compound) resembles Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Toremifene may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Berotralstat
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Berotralstat |
DB00465 | DB09135 | 886 | 1,211 | [
"DDInter1010",
"DDInter967"
] | Ketorolac | Ioxilan | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent. | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Major | 2 | [
[
[
886,
25,
1211
]
],
[
[
886,
24,
712
],
[
712,
25,
1211
]
],
[
[
886,
25,
1512
],
[
1512,
25,
1211
]
],
[
[
886,
63,
1645
],
[
1645,
... | [
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Ioxilan
Ketorolac may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Ioxilan
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may lead to a major life threatening interaction when taken with Ioxilan
Ketorolac (Compound) resembles Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Ioxilan
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Ketorolac may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may lead to a major life threatening interaction when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan |
DB00794 | DB01268 | 759 | 1,151 | [
"DDInter1521",
"DDInter1731"
] | Primidone | Sunitinib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Major | 2 | [
[
[
759,
25,
1151
]
],
[
[
759,
24,
1311
],
[
1311,
1,
1151
]
],
[
[
759,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
759,
21,
29209
],
[
29209,
... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopr... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Primidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Primidone (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Sunitinib (Compound)
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Primidone may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Primidone may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib |
DB01220 | DB09039 | 1,088 | 1,670 | [
"DDInter1593",
"DDInter629"
] | Rifaximin | Eliglustat | Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634] | Moderate | 1 | [
[
[
1088,
24,
1670
]
],
[
[
1088,
24,
943
],
[
943,
63,
1670
]
],
[
[
1088,
24,
478
],
[
478,
24,
1670
]
],
[
[
1088,
40,
690
],
[
690,
... | [
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
... | Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Rifaximin (Compound) resembles Rifabutin (Compound) and Rifabutin may lead to a major life threatening interaction when taken with Eliglustat
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Eliglustat
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Eliglustat
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat |
DB01285 | DB09104 | 708 | 286 | [
"DDInter445",
"DDInter1118"
] | Corticotropin | Magnesium hydroxide | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Moderate | 1 | [
[
[
708,
24,
286
]
],
[
[
708,
63,
88
],
[
88,
23,
286
]
],
[
[
708,
24,
729
],
[
729,
23,
286
]
],
[
[
708,
63,
1326
],
[
1326,
24,... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Corticotropin may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Corticotropin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may lead to a major life threatening interaction when taken with Magnesium hydroxide
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Patiromer and Patiromer may lead to a major life threatening interaction when taken with Magnesium hydroxide
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide |
DB00749 | DB08816 | 59 | 578 | [
"DDInter699",
"DDInter1802"
] | Etodolac | Ticagrelor | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Moderate | 1 | [
[
[
59,
24,
578
]
],
[
[
59,
21,
28762
],
[
28762,
60,
578
]
],
[
[
59,
63,
1578
],
[
1578,
24,
578
]
],
[
[
59,
64,
1172
],
[
1172,
... | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Etodolac",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by ... | Etodolac (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Etodolac may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Etodolac may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Etodolac may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Ticagrelor
Etodolac may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Ticagrelor |
DB01072 | DB01083 | 915 | 1,142 | [
"DDInter129",
"DDInter1348"
] | Atazanavir | Orlistat | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter and prescription preparations, depending on the dosage quantity. | Moderate | 1 | [
[
[
915,
24,
1142
]
],
[
[
915,
6,
8374
],
[
8374,
45,
1142
]
],
[
[
915,
21,
30409
],
[
30409,
60,
1142
]
],
[
[
915,
24,
5
],
[
5,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Atazanavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Atazanavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Atazanavir (Compound) causes Otitis (Side Effect) and Otitis (Side Effect) is caused by Orlistat (Compound)
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Atazanavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Atazanavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Orlistat (Compound)
Atazanavir (Compound) causes Otitis (Side Effect) and Otitis (Side Effect) is caused by Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Atazanavir (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Phylloquinone (Compound) and Phylloquinone may cause a minor interaction that can limit clinical effects when taken with Orlistat
Atazanavir (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Acarbose (Compound) and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Orlistat |
DB00019 | DB00072 | 1,257 | 550 | [
"DDInter1405",
"DDInter1846"
] | Pegfilgrastim | Trastuzumab | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia is less than 20% in many readily used chemotherapy regimens, infections pose risks of hospitalization and mortalities. Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop longer-acting pegfilgrastim.[A29,A187607] Due to a longer half-life and slower elimination rate than filgrastim | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells . Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly . In December 2017, FDA approved OGIVRI (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). It displays biosimilar properties as Herceptin according to clinical data. While Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the U.S. for the treatment of cancer. Herzuma (trastuzumab-pkrb) is a biosimilar drug approved in December 2018 for the treatment of HER2-overexpressing breast cancer. KANJINTI (trastuzumab-anns) is another biosimilar approved by the FDA in June 2019. ONTRUZANT, another biosimilar of Herceptin, was approved by Health Canada in February 2022.[L40303, L40308] In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda. | Moderate | 1 | [
[
[
1257,
24,
550
]
],
[
[
1257,
24,
869
],
[
869,
63,
550
]
],
[
[
1257,
24,
322
],
[
322,
64,
550
]
],
[
[
1257,
25,
1064
],
[
1064,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Trastuzumab
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Trastuzumab
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab |
DB11003 | DB11921 | 748 | 1,019 | [
"DDInter100",
"DDInter492"
] | Anthrax vaccine | Deflazacort | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340] | Moderate | 1 | [
[
[
748,
24,
1019
]
],
[
[
748,
24,
270
],
[
270,
63,
1019
]
],
[
[
748,
63,
629
],
[
629,
24,
1019
]
],
[
[
748,
24,
1316
],
[
1316,
... | [
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
... | Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab and Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Deflazacort
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Deflazacort
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Deflazacort
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Deflazacort |
DB00366 | DB00476 | 1,594 | 109 | [
"DDInter600",
"DDInter608"
] | Doxylamine | Duloxetine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more. | Moderate | 1 | [
[
[
1594,
24,
109
]
],
[
[
1594,
40,
847
],
[
847,
1,
109
]
],
[
[
1594,
24,
758
],
[
758,
1,
109
]
],
[
[
1594,
63,
1302
],
[
1302,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resemb... | Doxylamine (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) resembles Duloxetine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Duloxetine (Compound)
Doxylamine (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Duloxetine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine |
DB00092 | DB00688 | 58 | 955 | [
"DDInter40",
"DDInter1251"
] | Alefacept | Mycophenolate mofetil | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.[A180799,A180805] Previously, mycophenolic acid (MPA) was administered to individuals with autoimmune diseases beginning in the 1970s, but was discontinued due to gastrointestinal effects and concerns over carcinogenicity. The new semi-synthetic 2-morpholinoethyl ester of MPA was synthesized to avoid the gastrointestinal effects associated with the administration of MPA. It demonstrates an increased bioavailability, a higher efficacy, and reduced gastrointestinal effects when compared to MPA. | Moderate | 1 | [
[
[
58,
24,
955
]
],
[
[
58,
24,
1096
],
[
1096,
40,
955
]
],
[
[
58,
23,
1114
],
[
1114,
62,
955
]
],
[
[
58,
24,
1031
],
[
1031,
2... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Mycophenolate mofetil
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Mycophenolate mofetil
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Alefacept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Mycophenolate mofetil
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Mycophenolate mofetil
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mycophenolate mofetil |
DB00570 | DB08868 | 147 | 1,011 | [
"DDInter1936",
"DDInter737"
] | Vinblastine | Fingolimod | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
147,
25,
1011
]
],
[
[
147,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
147,
7,
9199
],
[
9199,
45,
1011
]
],
[
[
147,
21,
28714
],
[
28714... | [
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Vinblastine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingo... | Vinblastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Vinblastine (Compound) upregulates SPHK1 (Gene) and SPHK1 (Gene) is bound by Fingolimod (Compound)
Vinblastine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Fingolimod (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Vinblastine may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Vinblastine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod
Vinblastine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Fingolimod |
DB08889 | DB12834 | 350 | 148 | [
"DDInter299",
"DDInter1649"
] | Carfilzomib | Secnidazole | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy. | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen. Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades.[A245503, A245508] In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis. | Moderate | 1 | [
[
[
350,
24,
148
]
],
[
[
350,
63,
1593
],
[
1593,
24,
148
]
],
[
[
350,
24,
1480
],
[
1480,
24,
148
]
],
[
[
350,
64,
1510
],
[
1510,
... | [
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Carfilzomib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Carfilzomib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Colchicine and Colchicine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole |
DB00705 | DB00927 | 441 | 1,559 | [
"DDInter496",
"DDInter712"
] | Delavirdine | Famotidine | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings. | Moderate | 1 | [
[
[
441,
24,
1559
]
],
[
[
441,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
441,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
441,
24,
1384
],
[
138... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compoun... | Delavirdine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Delavirdine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a minor interaction that can limit clinical effects when taken with Famotidine
Delavirdine may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Famotidine
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Famotidine
Delavirdine may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Delavirdine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Delavirdine may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Famotidine |
DB00687 | DB11601 | 870 | 1,270 | [
"DDInter747",
"DDInter1889"
] | Fludrocortisone | Tuberculin purified protein derivative | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
870,
24,
1270
]
],
[
[
870,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
870,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
870,
1,
1486
],
[
1486,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fludrocortisone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fludrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fludrocortisone may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fludrocortisone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fludrocortisone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB00342 | DB11791 | 1,181 | 785 | [
"DDInter1770",
"DDInter287"
] | Terfenadine | Capmatinib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020, for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day. As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib's benefit in confirmatory trials. Capmatinib was approved by Health Canada on June 8, 2022. | Moderate | 1 | [
[
[
1181,
24,
785
]
],
[
[
1181,
25,
868
],
[
868,
24,
785
]
],
[
[
1181,
24,
322
],
[
322,
24,
785
]
],
[
[
1181,
64,
600
],
[
600,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemuraf... | Terfenadine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Terfenadine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Terfenadine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Capmatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Capmatinib
Terfenadine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Capmatinib |
DB00443 | DB01124 | 251 | 1,411 | [
"DDInter195",
"DDInter1828"
] | Betamethasone | Tolbutamide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Moderate | 1 | [
[
[
251,
24,
1411
]
],
[
[
251,
24,
959
],
[
959,
40,
1411
]
],
[
[
251,
63,
245
],
[
245,
40,
1411
]
],
[
[
251,
7,
2789
],
[
2789,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Betamethasone (Compound) upregulates PLCB3 (Gene) and PLCB3 (Gene) is upregulated by Tolbutamide (Compound)
Betamethasone (Compound) downregulates SPRED2 (Gene) and SPRED2 (Gene) is downregulated by Tolbutamide (Compound)
Betamethasone (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolbutamide (Compound)
Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide |
DB01122 | DB12267 | 158 | 1,476 | [
"DDInter61",
"DDInter233"
] | Ambenonium | Brigatinib | Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
158,
24,
1476
]
],
[
[
158,
24,
1276
],
[
1276,
24,
1476
]
],
[
[
158,
63,
1528
],
[
1528,
24,
1476
]
],
[
[
158,
24,
1011
],
[
1011,
... | [
[
[
"Ambenonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ambenonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
[
... | Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Brigatinib
Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Tacrine and Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine and Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Ambenonium (Compound) binds BCHE (Gene) and BCHE (Gene) is bound by Isoflurophate (Compound) and Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib |
DB00476 | DB06694 | 109 | 31 | [
"DDInter608",
"DDInter1952"
] | Duloxetine | Xylometazoline (nasal) | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more. | Xylometazoline is an alkylbenzene. | Moderate | 1 | [
[
[
109,
24,
31
]
],
[
[
109,
24,
144
],
[
144,
63,
31
]
],
[
[
109,
24,
1148
],
[
1148,
24,
31
]
],
[
[
109,
40,
1302
],
[
1302,
24... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Duloxetine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Duloxetine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Duloxetine may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Xylometazoline
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Duloxetine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Xylometazoline (Compound)
Duloxetine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline |
DB00279 | DB01359 | 1,152 | 729 | [
"DDInter1074",
"DDInter1417"
] | Liothyronine | Penbutolol | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956. | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the 5-hydroxytryptamine receptor 1A with antagonistic effects. This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity. | Minor | 0 | [
[
[
1152,
23,
729
]
],
[
[
1152,
23,
461
],
[
461,
1,
729
]
],
[
[
1152,
23,
699
],
[
699,
40,
729
]
],
[
[
1152,
21,
28882
],
[
28882,
... | [
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Penbutolol"
]
],
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
],
[
... | Liothyronine may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Liothyronine may cause a minor interaction that can limit clinical effects when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Liothyronine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Penbutolol (Compound)
Liothyronine (Compound) resembles Levothyroxine (Compound) and Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Penbutolol
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Penbutolol
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Penbutolol
Liothyronine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Penbutolol
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate and Calcium citrate may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol |
DB11601 | DB11793 | 1,270 | 738 | [
"DDInter1889",
"DDInter1297"
] | Tuberculin purified protein derivative | Niraparib | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019. | Moderate | 1 | [
[
[
1270,
24,
738
]
],
[
[
1270,
63,
1213
],
[
1213,
24,
738
]
],
[
[
1270,
24,
1619
],
[
1619,
63,
738
]
],
[
[
1270,
24,
351
],
[
351,
... | [
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases w... | Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Niraparib
Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Niraparib
Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib |
DB01159 | DB13074 | 419 | 877 | [
"DDInter854",
"DDInter1110"
] | Halothane | Macimorelin | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Major | 2 | [
[
[
419,
25,
877
]
],
[
[
419,
62,
112
],
[
112,
23,
877
]
],
[
[
419,
24,
913
],
[
913,
24,
877
]
],
[
[
419,
63,
770
],
[
770,
24,... | [
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Halothane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Halothane may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Macimorelin
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Macimorelin
Halothane may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Macimorelin
Halothane may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Macimorelin
Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin |
DB00701 | DB01190 | 1,091 | 568 | [
"DDInter90",
"DDInter398"
] | Amprenavir | Clindamycin | Amprenavir is a protease inhibitor used to treat HIV infection. | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis. Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from _Streptomyces lincolnensis_ found in a soil sample. | Moderate | 1 | [
[
[
1091,
24,
568
]
],
[
[
1091,
6,
8374
],
[
8374,
45,
568
]
],
[
[
1091,
21,
29278
],
[
29278,
60,
568
]
],
[
[
1091,
23,
609
],
[
609,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Amprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Amprenavir (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Clindamycin (Compound)
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Amprenavir (Compound) resembles Fosamprenavir (Compound) and Fos
Amprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Amprenavir (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Amprenavir (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Lincomycin (Compound) and Lincomycin (Compound) resembles Clindamycin (Compound)
Amprenavir (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Gentamicin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin |
DB00316 | DB00682 | 474 | 126 | [
"DDInter14",
"DDInter1951"
] | Acetaminophen | Warfarin | Acetaminophen (paracetamol), also commonly known as _Tylenol_, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the U.S. FDA in 1951 and is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms.[L5756,L5774,F4124,Label] Acetaminophen is often found combined with other drugs in more than 600 over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products. Confusion about dosing of this drug may be caused by the availability of different formulas, strengths, and dosage instructions for children of different ages. Due to the possibility of fatal overdose and liver | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Moderate | 1 | [
[
[
474,
24,
126
]
],
[
[
474,
6,
3486
],
[
3486,
45,
126
]
],
[
[
474,
24,
663
],
[
663,
23,
126
]
],
[
[
474,
24,
1017
],
[
1017,
... | [
[
[
"Acetaminophen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Acetaminophen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compoun... | Acetaminophen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Warfarin (Compound)
Acetaminophen may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin
Acetaminophen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Acetaminophen may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Acetaminophen may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Acetaminophen may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Acetaminophen may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Acetaminophen may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Warfarin
Acetaminophen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Warfarin (Compound) |
DB00677 | DB12267 | 775 | 1,476 | [
"DDInter984",
"DDInter233"
] | Isoflurophate (ophthalmic) | Brigatinib | Diisopropyl fluorophosphate is a dialkyl phosphate. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
775,
24,
1476
]
],
[
[
775,
24,
1276
],
[
1276,
24,
1476
]
],
[
[
775,
24,
1011
],
[
1011,
25,
1476
]
],
[
[
775,
24,
1276
],
[
1276,
... | [
[
[
"Isoflurophate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Isoflurophate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
... | Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Brigatinib
Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Tacrine and Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Isoflurophate (Compound) binds BCHE (Gene) and BCHE (Gene) is bound by Edrophonium (Compound) and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Isoflurophate (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib |
DB00794 | DB08901 | 759 | 1,468 | [
"DDInter1521",
"DDInter1492"
] | Primidone | Ponatinib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
759,
24,
1468
]
],
[
[
759,
25,
478
],
[
478,
24,
1468
]
],
[
[
759,
6,
3486
],
[
3486,
45,
1468
]
],
[
[
759,
18,
3741
],
[
3741,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
... | Primidone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Primidone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Primidone (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Ponatinib (Compound)
Primidone (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Ponatinib (Compound)
Primidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Primidone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Primidone may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib |
DB01116 | DB08907 | 601 | 1,344 | [
"DDInter1872",
"DDInter280"
] | Trimethaphan | Canagliflozin | A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
601,
24,
1344
]
],
[
[
601,
24,
549
],
[
549,
1,
1344
]
],
[
[
601,
63,
1486
],
[
1486,
24,
1344
]
],
[
[
601,
24,
1019
],
[
1019,
... | [
[
[
"Trimethaphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Trimethaphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]... | Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Trimethaphan (Compound) resembles Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) binds SLC5A1 (Gene) and SLC5A1 (Gene) is bound by Canagliflozin (Compound)
Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Trimethaphan (Compound) resembles Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound) |
DB00468 | DB00582 | 1,424 | 1,622 | [
"DDInter1557",
"DDInter1946"
] | Quinine | Voriconazole | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002. | Moderate | 1 | [
[
[
1424,
24,
1622
]
],
[
[
1424,
6,
21998
],
[
21998,
45,
1622
]
],
[
[
1424,
21,
29076
],
[
29076,
60,
1622
]
],
[
[
1424,
23,
752
],
[
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v... | Quinine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Voriconazole (Compound)
Quinine (Compound) causes Liver function test abnormal (Side Effect) and Liver function test abnormal (Side Effect) is caused by Voriconazole (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Quinine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Voriconazole |
DB04948 | DB12141 | 1,084 | 971 | [
"DDInter1083",
"DDInter817"
] | Lofexidine | Gilteritinib | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
1084,
24,
971
]
],
[
[
1084,
62,
112
],
[
112,
23,
971
]
],
[
[
1084,
63,
485
],
[
485,
24,
971
]
],
[
[
1084,
24,
823
],
[
823,
... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Lofexidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Lofexidine may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Gilteritinib
Lofexidine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Gilteritinib
Lofexidine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Gilteritinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Gilteritinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Gilteritinib |
DB00731 | DB01032 | 1,144 | 824 | [
"DDInter1269",
"DDInter1522"
] | Nateglinide | Probenecid | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. | Moderate | 1 | [
[
[
1144,
24,
824
]
],
[
[
1144,
24,
1411
],
[
1411,
63,
824
]
],
[
[
1144,
6,
8374
],
[
8374,
45,
824
]
],
[
[
1144,
21,
28722
],
[
28722... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probenecid"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid
Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Probenecid (Compound)
Nateglinide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Probenecid (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Probenecid
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Probenecid
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Probenecid
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Probenecid
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Probenecid (Compound)
Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diclofenac (Compound) and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Probenecid |
DB08889 | DB11995 | 350 | 1,634 | [
"DDInter299",
"DDInter143"
] | Carfilzomib | Avatrombopag | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy. | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require platelet transfusions before surgical procedures to decrease the risk of bleeding. Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy. Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. It is administered orally as the salt form avatrombopag maleate. _Doptelet_ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before a procedure by increasing platelet counts to the optimal level ≥50,000 per microliter. | Major | 2 | [
[
[
350,
25,
1634
]
],
[
[
350,
24,
1613
],
[
1613,
24,
1634
]
],
[
[
350,
63,
912
],
[
912,
24,
1634
]
],
[
[
350,
24,
1613
],
[
1613,
... | [
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avatrombopag"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Carfilzomib (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Voriconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Primidone and Primidone may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag |
DB00213 | DB05294 | 837 | 1,069 | [
"DDInter1388",
"DDInter1917"
] | Pantoprazole | Vandetanib | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Minor | 0 | [
[
[
837,
23,
1069
]
],
[
[
837,
25,
1195
],
[
1195,
40,
1069
]
],
[
[
837,
24,
883
],
[
883,
40,
1069
]
],
[
[
837,
6,
17404
],
[
17404,
... | [
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vandetanib"
]
],
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erlotinib"
],
[
"Erlotinib... | Pantoprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Vandetanib (Compound)
Pantoprazole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Vandetanib (Compound)
Pantoprazole (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Vandetanib (Compound)
Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Vandetanib
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may lead to a major life threatening interaction when taken with Vandetanib
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may lead to a major life threatening interaction when taken with Vandetanib |
DB00790 | DB06723 | 664 | 115 | [
"DDInter1431",
"DDInter58"
] | Perindopril | Aluminum hydroxide | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
664,
23,
115
]
],
[
[
664,
21,
28845
],
[
28845,
60,
115
]
],
[
[
664,
40,
1058
],
[
1058,
23,
115
]
],
[
[
664,
63,
870
],
[
870,
... | [
[
[
"Perindopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Perindopril",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is ca... | Perindopril (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Aluminum hydroxide (Compound)
Perindopril (Compound) resembles Moexipril (Compound) and Moexipril may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Perindopril (Compound) resembles Quinapril (Compound) and Quinapril may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Perindopril may cause a minor interaction that can limit clinical effects when taken with Sodium citrate and Sodium citrate may lead to a major life threatening interaction when taken with Aluminum hydroxide
Perindopril (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Fludrocortisone (Compound) and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide |
DB09570 | DB15965 | 1,480 | 1,330 | [
"DDInter1002",
"DDInter1270"
] | Ixazomib | Naxitamab | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors), and is rarely subject to antigen loss. The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies, making the administration of naxitamab therapy markedly simpler than that of its predecessor. | Moderate | 1 | [
[
[
1480,
24,
1330
]
],
[
[
1480,
63,
14
],
[
14,
24,
1330
]
],
[
[
1480,
24,
148
],
[
148,
24,
1330
]
],
[
[
1480,
64,
375
],
[
375,
... | [
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
... | Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ixazomib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Naxitamab
Ixazomib may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Naxitamab
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab |
DB04865 | DB13928 | 4 | 1,385 | [
"DDInter1335",
"DDInter1660"
] | Omacetaxine mepesuccinate | Semaglutide | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective. | Moderate | 1 | [
[
[
4,
24,
1385
]
],
[
[
4,
24,
637
],
[
637,
24,
1385
]
],
[
[
4,
63,
891
],
[
891,
24,
1385
]
],
[
[
4,
64,
695
],
[
695,
24,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Semaglutide
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide |
DB01319 | DB11703 | 34 | 405 | [
"DDInter777",
"DDInter9"
] | Fosamprenavir | Acalabrutinib | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib . | Major | 2 | [
[
[
34,
25,
405
]
],
[
[
34,
63,
1051
],
[
1051,
24,
405
]
],
[
[
34,
25,
951
],
[
951,
24,
405
]
],
[
[
34,
25,
982
],
[
982,
63,
... | [
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
... | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Fosamprenavir may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Fosamprenavir may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Fosamprenavir may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Acalabrutinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Acalabrutinib |
DB00758 | DB06754 | 1,347 | 707 | [
"DDInter413",
"DDInter471"
] | Clopidogrel | Danaparoid | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997. | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously. | Major | 2 | [
[
[
1347,
25,
707
]
],
[
[
1347,
23,
944
],
[
944,
62,
707
]
],
[
[
1347,
24,
1496
],
[
1496,
63,
707
]
],
[
[
1347,
24,
901
],
[
901,
... | [
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",... | Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin and Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Clopidogrel may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Clopidogrel may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Danaparoid
Clopidogrel may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Danaparoid
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may lead to a major life threatening interaction when taken with Danaparoid
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Alteplase and Alteplase may lead to a major life threatening interaction when taken with Danaparoid |
DB06273 | DB14711 | 980 | 779 | [
"DDInter1824",
"DDInter1680"
] | Tocilizumab | Smallpox (Vaccinia) Vaccine, Live | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tociliz | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
980,
25,
779
]
],
[
[
980,
64,
1064
],
[
1064,
25,
779
]
],
[
[
980,
63,
147
],
[
147,
25,
779
]
],
[
[
980,
25,
1259
],
[
1259,
... | [
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"... | Tocilizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tocilizumab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tocilizumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tocilizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tocilizumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live |
DB00719 | DB01057 | 1,219 | 1,318 | [
"DDInter149",
"DDInter615"
] | Azatadine | Echothiophate (ophthalmic) | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. | Ecothiopate is the phosphorothioate obtained by formal condensation of diethyl phosphate with N,N,N-trimethyl-2-sulfanylethanaminium. An irreversible acetylcholinesterase inhibitor, its iodide salt is used an ocular antihypertensive in the treatment of open-angle glaucoma, particularly when other drugs have proved inadequate. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor and a miotic. It is an organic thiophosphate, a member of phosphocholines and a quaternary ammonium ion. | Moderate | 1 | [
[
[
1219,
24,
1318
]
],
[
[
1219,
40,
830
],
[
830,
63,
1318
]
],
[
[
1219,
24,
100
],
[
100,
24,
1318
]
],
[
[
1219,
24,
272
],
[
272,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Echothiophate"
]
],
[
[
"Azatadine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a mo... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Echothiophate
Azatadine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Echothiophate
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Echothiophate
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Echothiophate
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Echothiophate
Azatadine (Compound) resembles Phenindamine (Compound) and Phenindamine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Echothiophate
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Echothiophate
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Echothiophate (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium (Compound) binds BCHE (Gene) and BCHE (Gene) is bound by Echothiophate (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Echothiophate (Compound) |
DB00285 | DB09065 | 1,100 | 760 | [
"DDInter1927",
"DDInter424"
] | Venlafaxine | Cobicistat | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venl | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. | Moderate | 1 | [
[
[
1100,
24,
760
]
],
[
[
1100,
24,
1374
],
[
1374,
23,
760
]
],
[
[
1100,
24,
723
],
[
723,
24,
760
]
],
[
[
1100,
40,
534
],
[
534,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Venlafaxine (Compound) resembles Tramadol (Compound) and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Venlafaxine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Venlafaxine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Cobicistat
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Cobicistat
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Cobicistat |
DB00288 | DB01124 | 1,103 | 1,411 | [
"DDInter63",
"DDInter1828"
] | Amcinonide | Tolbutamide | Amcinonide is a corticosteroid. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Minor | 0 | [
[
[
1103,
23,
1411
]
],
[
[
1103,
23,
959
],
[
959,
40,
1411
]
],
[
[
1103,
62,
245
],
[
245,
40,
1411
]
],
[
[
1103,
21,
28703
],
[
28703... | [
[
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
]
],
[
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glipizide"
],
[
... | Amcinonide may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Amcinonide may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Amcinonide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Tolbutamide (Compound)
Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Amcinonide (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Amcinonide may cause a minor interaction that can limit clinical effects when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Amcinonide (Compound) resembles Fluoxymesterone (Compound) and Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Amcinonide (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide |
DB00213 | DB01416 | 837 | 1,024 | [
"DDInter1388",
"DDInter326"
] | Pantoprazole | Cefpodoxime | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups | Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | Moderate | 1 | [
[
[
837,
24,
1024
]
],
[
[
837,
24,
665
],
[
665,
40,
1024
]
],
[
[
837,
24,
1462
],
[
1462,
1,
1024
]
],
[
[
837,
21,
29044
],
[
29044,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefpodoxime (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Cefpodoxime (Compound)
Pantoprazole (Compound) causes Pneumonia (Side Effect) and Pneumonia (Side Effect) is caused by Cefpodoxime (Compound)
Pantoprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefpodoxime
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefpodoxime
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Ceftriaxone (Compound) and Ceftriaxone (Compound) resembles Cefpodoxime (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Ceftriaxone (Compound) and Ceftriaxone (Compound) resembles Cefpodoxime (Compound)
Pantoprazole (Compound) causes Pneumonia (Side Effect) and Pneumonia (Side Effect) is caused by Cefepime (Compound) and Cefepime (Compound) resembles Cefpodoxime (Compound)
Pantoprazole (Compound) causes Rectal haemorrhage (Side Effect) and Rectal haemorrhage (Side Effect) is caused by Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefpodoxime |
DB00590 | DB01246 | 1,433 | 820 | [
"DDInter592",
"DDInter45"
] | Doxazosin | Alimemazine | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1433,
24,
820
]
],
[
[
1433,
24,
104
],
[
104,
40,
820
]
],
[
[
1433,
24,
401
],
[
401,
24,
820
]
],
[
[
1433,
21,
28662
],
[
28662,
... | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Doxazosin (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Alimemazine (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Doxazosin (Compound) resembles Donepezil (Compound) and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Doxazosin (Compound) resembles Prazosin (Compound) and Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Alimemazine
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Alimemazine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine |
DB00685 | DB01101 | 1,299 | 60 | [
"DDInter1887",
"DDInter285"
] | Trovafloxacin | Capecitabine | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Minor | 0 | [
[
[
1299,
23,
60
]
],
[
[
1299,
21,
28906
],
[
28906,
60,
60
]
],
[
[
1299,
1,
872
],
[
872,
62,
60
]
],
[
[
1299,
24,
460
],
[
460,
... | [
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastroenteritis"
],
[
"Gastroenteritis",
"{u} (Si... | Trovafloxacin (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused by Capecitabine (Compound)
Trovafloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Trovafloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine |
DB00687 | DB01208 | 870 | 945 | [
"DDInter747",
"DDInter1705"
] | Fludrocortisone | Sparfloxacin | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
870,
25,
945
]
],
[
[
870,
25,
739
],
[
739,
1,
945
]
],
[
[
870,
64,
1176
],
[
1176,
1,
945
]
],
[
[
870,
21,
28814
],
[
28814,
... | [
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxaci... | Fludrocortisone may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Fludrocortisone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Fludrocortisone (Compound) causes Affect lability (Side Effect) and Affect lability (Side Effect) is caused by Sparfloxacin (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin |
DB01263 | DB06176 | 859 | 1,342 | [
"DDInter1494",
"DDInter1616"
] | Posaconazole | Romidepsin | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
859,
24,
1342
]
],
[
[
859,
62,
112
],
[
112,
23,
1342
]
],
[
[
859,
63,
485
],
[
485,
24,
1342
]
],
[
[
859,
24,
1616
],
[
1616,
... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Posaconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Posaconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Posaconazole may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Posaconazole may lead to a major life threatening interaction when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Posaconazole may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Romidepsin
Posaconazole may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Romidepsin
Posaconazole may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Romidepsin |
DB00543 | DB00619 | 87 | 1,419 | [
"DDInter82",
"DDInter909"
] | Amoxapine | Imatinib | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Moderate | 1 | [
[
[
87,
24,
1419
]
],
[
[
87,
6,
12523
],
[
12523,
45,
1419
]
],
[
[
87,
21,
28762
],
[
28762,
60,
1419
]
],
[
[
87,
25,
222
],
[
222,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Amoxapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Amoxapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Imatinib (Compound)
Amoxapine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Imatinib (Compound)
Amoxapine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Imatinib
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Amoxapine (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Amoxapine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Amoxapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib |
DB00404 | DB06282 | 523 | 516 | [
"DDInter54",
"DDInter1053"
] | Alprazolam | Levocetirizine | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
523,
24,
516
]
],
[
[
523,
62,
1031
],
[
1031,
23,
516
]
],
[
[
523,
24,
1074
],
[
1074,
63,
516
]
],
[
[
523,
63,
701
],
[
701,
... | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
... | Alprazolam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Alprazolam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Alprazolam (Compound) resembles Temazepam (Compound) and Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Alprazolam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Alprazolam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine |
DB01064 | DB01168 | 1,148 | 1,053 | [
"DDInter987",
"DDInter1526"
] | Isoprenaline | Procarbazine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1148,
24,
1053
]
],
[
[
1148,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1148,
64,
246
],
[
246,
23,
1053
]
],
[
[
1148,
63,
739
],
[
739... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is ... | Isoprenaline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Isoprenaline may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Isoprenaline may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Isoprenaline may lead to a major life threatening interaction when taken with Bepridil and Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine |
DB00721 | DB00795 | 1,207 | 50 | [
"DDInter1525",
"DDInter1725"
] | Procaine | Sulfasalazine | A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients. | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease. Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine is not FDA-recommmended for treatment of Crohn's disease.[A255597,A255602,A255607] | Moderate | 1 | [
[
[
1207,
24,
50
]
],
[
[
1207,
18,
18226
],
[
18226,
57,
50
]
],
[
[
1207,
25,
1455
],
[
1455,
64,
50
]
],
[
[
1207,
18,
18226
],
[
18226... | [
[
[
"Procaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Procaine",
"{u} (Compound) downregulates {v} (Gene)",
"GDF15"
],
[
"GDF15",
"{u} (Gene) is downregulated by {v}... | Procaine (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Sulfasalazine (Compound)
Procaine may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Sulfasalazine
Procaine (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is regulated by ABCC2 (Gene) and ABCC2 (Gene) is bound by Sulfasalazine (Compound)
Procaine (Compound) resembles Metoclopramide (Compound) and Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Procaine may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine (Compound)
Procaine (Compound) resembles Procainamide (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Ioversol and Ioversol may lead to a major life threatening interaction when taken with Sulfasalazine
Procaine (Compound) resembles Metoclopramide (Compound) and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Sulfasalazine
Procaine may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Sulfasalazine
Procaine (Compound) resembles Probenecid (Compound) and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine |
DB00366 | DB11823 | 1,594 | 858 | [
"DDInter600",
"DDInter673"
] | Doxylamine | Esketamine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970. Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications and therapies. The intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to take effect. | Moderate | 1 | [
[
[
1594,
24,
858
]
],
[
[
1594,
35,
272
],
[
272,
24,
858
]
],
[
[
1594,
24,
506
],
[
506,
24,
858
]
],
[
[
1594,
63,
1242
],
[
1242,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken w... | Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Doxylamine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Esketamine
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Chlorpheniramine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine |
DB00771 | DB01224 | 262 | 623 | [
"DDInter397",
"DDInter1553"
] | Clidinium | Quetiapine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine]. | Moderate | 1 | [
[
[
262,
24,
623
]
],
[
[
262,
63,
695
],
[
695,
1,
623
]
],
[
[
262,
24,
1178
],
[
1178,
1,
623
]
],
[
[
262,
6,
7992
],
[
7992,
45... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Quetiapine (Compound)
Clidinium (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Quetiapine (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium and Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Clidinium (Compound) resembles Trospium (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Quetiapine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Quetiapine |
DB00963 | DB01124 | 1,263 | 1,411 | [
"DDInter241",
"DDInter1828"
] | Bromfenac | Tolbutamide | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Moderate | 1 | [
[
[
1263,
24,
1411
]
],
[
[
1263,
24,
959
],
[
959,
40,
1411
]
],
[
[
1263,
63,
245
],
[
245,
40,
1411
]
],
[
[
1263,
18,
9205
],
[
9205,
... | [
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Bromfenac (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Tolbutamide (Compound)
Bromfenac (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Tolbutamide (Compound)
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Bromfenac (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Bromfenac may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide |
DB00023 | DB00065 | 305 | 581 | [
"DDInter127",
"DDInter923"
] | Asparaginase Escherichia coli | Infliximab | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases . Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α , infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α . Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondyliti, psoriatic arthritis, and plaque psoriasis [FDA Label]. In clinical trials, multiple infusions of infliximab displayed in a reduction of signs and symptoms of inflammatory diseases and induction of remission in patients who have had an inadequate response to alternative first-line therapies for that disorder [FDA Label]. There are currently two biosilimars of infliximab available in the US market that demonstrate a high degree of similarity to the reference product, Remicade. They are approved for all eligible indications of the reference product. Inflectra, a first biosimilar drug product, was approved in 2016. In December 2017, Ixifi, a second biosimilar that was developed by Pfizer, was granted approval by the FDA. | Major | 2 | [
[
[
305,
25,
581
]
],
[
[
305,
24,
221
],
[
221,
63,
581
]
],
[
[
305,
24,
912
],
[
912,
24,
581
]
],
[
[
305,
63,
1451
],
[
1451,
2... | [
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poli... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Infliximab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may lead to a major life threatening interaction when taken with Infliximab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Infliximab
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Infliximab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Infliximab |
DB01236 | DB11978 | 679 | 124 | [
"DDInter1664",
"DDInter822"
] | Sevoflurane | Glasdegib | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile. | Moderate | 1 | [
[
[
679,
24,
124
]
],
[
[
679,
62,
112
],
[
112,
23,
124
]
],
[
[
679,
63,
475
],
[
475,
24,
124
]
],
[
[
679,
24,
1342
],
[
1342,
2... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Sevoflurane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Sevoflurane (Compound) resembles Perflutren (Compound) and Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Sevoflurane may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Glasdegib
Sevoflurane may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Glasdegib
Sevoflurane may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Glasdegib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Glasdegib |
DB00341 | DB00832 | 1,242 | 499 | [
"DDInter343",
"DDInter1446"
] | Cetirizine | Phensuximide | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals. Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects. Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor | Phensuximide is a member of the succinimide class with anticonvulsant properties. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. | Moderate | 1 | [
[
[
1242,
24,
499
]
],
[
[
1242,
24,
902
],
[
902,
40,
499
]
],
[
[
1242,
24,
849
],
[
849,
63,
499
]
],
[
[
1242,
24,
1594
],
[
1594,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phensuximide"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Phensuximide (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide
Cetirizine (Compound) resembles Clemastine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Diazepam (Compound) and Diazepam (Compound) resembles Phensuximide (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin and Ethotoin (Compound) resembles Phenmetrazine (Compound) and Phenmetrazine (Compound) resembles Phensuximide (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Phensuximide (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Clobazam and Clobazam (Compound) resembles Phensuximide (Compound) |
DB00106 | DB01044 | 618 | 246 | [
"DDInter4",
"DDInter809"
] | Abarelix | Gatifloxacin | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Major | 2 | [
[
[
618,
25,
246
]
],
[
[
618,
25,
1176
],
[
1176,
1,
246
]
],
[
[
618,
24,
872
],
[
872,
40,
246
]
],
[
[
618,
23,
112
],
[
112,
23... | [
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u}... | Abarelix may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Gatifloxacin (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may lead to a major life threatening interaction when taken with Gatifloxacin
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may lead to a major life threatening interaction when taken with Gatifloxacin
Abarelix may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Gatifloxacin
Abarelix may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Gatifloxacin |
DB00682 | DB09117 | 126 | 957 | [
"DDInter1951",
"DDInter1391"
] | Warfarin | Paraldehyde | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo effect. | Minor | 0 | [
[
[
126,
23,
957
]
],
[
[
126,
24,
1264
],
[
1264,
24,
957
]
],
[
[
126,
1,
1376
],
[
1376,
24,
957
]
],
[
[
126,
24,
1264
],
[
1264,
... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paraldehyde"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Dox... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Warfarin (Compound) resembles Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Warfarin (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Warfarin (Compound) resembles Diphenhydramine (Compound) and Diphenhydramine (Compound) resembles Doxepin (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Warfarin (Compound) resembles Phenindione (Compound) and Phenindione (Compound) resembles Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Warfarin (Compound) resembles Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde |
DB01210 | DB09333 | 668 | 278 | [
"DDInter1050",
"DDInter963"
] | Levobunolol (ophthalmic) | Iopodic acid | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrenergic antagonist. It is a propanolamine, a cyclic ketone and an aromatic ether. It is a conjugate acid of a levobunolol(1+). It derives from a hydride of a tetralin. | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO. This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada. On September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status. | Moderate | 1 | [
[
[
668,
24,
278
]
],
[
[
668,
40,
461
],
[
461,
24,
278
]
],
[
[
668,
24,
1527
],
[
1527,
24,
278
]
],
[
[
668,
63,
808
],
[
808,
2... | [
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound)",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate ... | Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol (Compound) resembles Timolol (Compound) and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid and Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol (Compound) resembles Nadolol (Compound) and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol (Compound) resembles Timolol (Compound) and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid and Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol (Compound) resembles Nadolol (Compound) and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a minor interaction that can limit clinical effects when taken with Cholestyramine and Cholestyramine may cause a minor interaction that can limit clinical effects when taken with Iopodic acid |
DB08889 | DB09121 | 350 | 1,328 | [
"DDInter299",
"DDInter140"
] | Carfilzomib | Aurothioglucose | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy. | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and slow onset of action. Many if not most gold compounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and others, which are far more effective. | Moderate | 1 | [
[
[
350,
24,
1328
]
],
[
[
350,
63,
367
],
[
367,
24,
1328
]
],
[
[
350,
64,
581
],
[
581,
24,
1328
]
],
[
[
350,
25,
375
],
[
375,
... | [
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carfilzomib may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carfilzomib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Aurothioglucose
Carfilzomib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Aurothioglucose
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carfilzomib may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose |
DB00795 | DB13874 | 50 | 1,501 | [
"DDInter1725",
"DDInter639"
] | Sulfasalazine | Enasidenib | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017. | Moderate | 1 | [
[
[
50,
24,
1501
]
],
[
[
50,
63,
663
],
[
663,
24,
1501
]
],
[
[
50,
24,
1619
],
[
1619,
24,
1501
]
],
[
[
50,
25,
1510
],
[
1510,
... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Sulfasalazine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Sulfasalazine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Sulfasalazine (Compound) treats ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib |
DB00804 | DB14881 | 1,507 | 180 | [
"DDInter543",
"DDInter1329"
] | Dicyclomine | Oliceridine | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable. Dicyclomine was granted FDA approval on 11 May 1950. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™. | Moderate | 1 | [
[
[
1507,
24,
180
]
],
[
[
1507,
24,
401
],
[
401,
24,
180
]
],
[
[
1507,
63,
85
],
[
85,
24,
180
]
],
[
[
1507,
63,
1425
],
[
1425,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Oliceridine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine |
DB01234 | DB13179 | 1,220 | 68 | [
"DDInter513",
"DDInter1882"
] | Dexamethasone | Troleandomycin | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
1220,
24,
68
]
],
[
[
1220,
63,
1101
],
[
1101,
23,
68
]
],
[
[
1220,
25,
466
],
[
466,
23,
68
]
],
[
[
1220,
24,
309
],
[
309,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Dexamethasone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Dexamethasone (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Troleandomycin |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.